New Treatments & Clinical Trials for Myositis

Myositis describes inflammatory muscle diseases that cause weakness, pain, and fatigue. The main types — dermatomyositis, polymyositis, and immune-mediated necrotizing myopathy — each have distinct patterns of muscle damage. Treatment usually starts with steroids, but many people need additional immunosuppressive drugs to control their disease and reduce side effects.

What's actually going on in research

Trials are testing targeted treatments that block specific immune pathways, including JAK inhibitors already approved for other autoimmune diseases, and drugs that deplete B cells or block complement proteins. Researchers are also studying intravenous immunoglobulin timing, combination approaches to reduce steroid use, and biomarkers that predict which myositis subtype someone has and how they'll respond to treatment.

What to know before you search

Eligibility typically depends on myositis subtype, disease activity measured by muscle enzymes or strength testing, autoantibody status, and what treatments you've already tried.

What types of trials are currently open

• Treatment trials — Testing new immunosuppressive drugs, often pills like JAK inhibitors, to see if they control muscle inflammation better than current options or allow lower steroid doses.
• Combination therapy trials — Studies that add a new drug to standard treatment, aiming to improve muscle strength while reducing prednisone side effects.
• Subtype-specific trials — Testing treatments in people with a particular myositis type or autoantibody pattern, where disease mechanisms may differ.
• Registry studies — Following people with myositis over time to learn which treatments work best for different subtypes and what predicts lung or heart involvement.
• Skin and muscle repair — Trials focused on dermatomyositis rash or muscle rehabilitation, testing whether treatments can heal damage rather than just suppress inflammation.